We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going ...

RBC Capital lowered the firm’s price target on Apellis (APLS) to $21 from $24 and keeps a Sector Perform rating on the shares. The firm has ...

Pharmaceuticals announced that Craig Wheeler, founder and chief executive officer of Headwaters Biotech Advisors, will join the ...

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Craig Wheeler, founder and chief executive officer of Headwaters Biotech Advisors, will join the Apellis Board of Directors, effective ...

After several weeks and thousands of votes, TV drug ads from Apellis Pharmaceuticals and AstraZeneca found themselves in the final round of the annual #FierceMadness bracket competition. | After ...

BioHarvest Sciences Inc. BHST shares ended the last trading session 5.2% higher at $5.90. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

A Prescription Drug User Fee Act target date of July 28, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has granted Priority Review to pegcetacoplan for the ...

Apellis Pharmaceuticals has a 1 year low of $19.76 and a 1 year high of $57.85. The firm has a market cap of $2.51 billion, a price-to-earnings ratio of -9.84 and a beta of 0.85.

Apellis Pharmaceuticals, Inc.’s APLS share price has dipped by 11.32%, which has investors questioning if this is right time to buy.